<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04119388</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0747</org_study_id>
    <secondary_id>ID-RCB</secondary_id>
    <nct_id>NCT04119388</nct_id>
  </id_info>
  <brief_title>Evaluation of the Benefits of Adaptive Physical Activity in Children and Adolescents With Osteogenesis Imperfecta</brief_title>
  <acronym>MOVE-OI</acronym>
  <official_title>Evaluation of the Benefits of Adaptive Physical Activity in Children and Adolescents With Osteogenesis Imperfecta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteogenesis imperfecta (OI) is a rare genetic disorder of increased bone fragility and low
      bone mass. It is conceivable that children and adolescents with OI are less active than
      healthy peers because of frequent fractures, immobilization,functionals limitations and no
      adapted physicals activity(APA). The hypothesis is that an Adapted physique activity could
      improve access of activity for patients with Osteogenesis Imperfecta (OI).

      The aim of the study is to evaluate benefice of APA,improve aerobic capacity, cardiovascular
      and bone benefits, and gain of quality of life.

      Children with OI between 6 and 18 years old will have a program of supervised &quot;adapted
      training program&quot; during one year. The program is adapted at each individual and without risk
      for the patient.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 minutes walk test</measure>
    <time_frame>Month 0</time_frame>
    <description>Distance traveled (in meters) in 6 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 minutes walk test</measure>
    <time_frame>Month 6</time_frame>
    <description>Distance traveled (in meters) in 6 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6 minutes walk test</measure>
    <time_frame>Month 12</time_frame>
    <description>Distance traveled (in meters) in 6 minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Month 0</time_frame>
    <description>weight in kilograms will be measured with a scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Month 6</time_frame>
    <description>weight in kilograms will be measured with a scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Month 12</time_frame>
    <description>weight in kilograms will be measured with a scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height</measure>
    <time_frame>Month 0</time_frame>
    <description>Size in meter measured with a meter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height</measure>
    <time_frame>Month 6</time_frame>
    <description>Size in meter measured with a meter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height</measure>
    <time_frame>Month 12</time_frame>
    <description>Size in meter measured with a meter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body mass index</measure>
    <time_frame>Month 0</time_frame>
    <description>calculated with weight and height</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body mass index</measure>
    <time_frame>Month 6</time_frame>
    <description>calculated with weight and height</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body mass index</measure>
    <time_frame>Month 12</time_frame>
    <description>calculated with weight and height</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>Month 0</time_frame>
    <description>measurement of blood pressure (cm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>Month 6</time_frame>
    <description>measurement of blood pressure (cm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>Month 12</time_frame>
    <description>measurement of blood pressure (cm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>Ionosodium (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>potassium (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>calcium (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>chlore (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>bicarbonates (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>glucose (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>urea (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>creatinemia (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>phosphorus (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>proteinemia (g/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>Vitamin D (nmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>1-25 OH vitamin D (pmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>PTH (ng/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>alkaline bone phosphatases (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>CTX (pg/ml)crosslaps</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>osteocalcin (µg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>ferritin (µg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>blood count formula : leucocytes (giga/L), erythrocytes (tera/L), hemoglobin (g/L), hematocrit (%), platelets (giga/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>calciuria (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphocalcic biologic parameters</measure>
    <time_frame>Month 0 and Month 12</time_frame>
    <description>Ionosodium (mmol/L) potassium (mmol/L), calcium (mmol/L), chlore (mmol/L), bicarbonates (mmol/L), glucose (mmol/L), urea (mmol/L), creatinemia (mmol/L), phosphorus (mmol/L), proteinemia (g/L), Vitamin D (nmol/L), 1-25 OH vitamin D (pmol/L), PTH (ng/L), alkaline bone phosphatases (U/L), CTX (pg/ml)crosslaps, osteocalcin (µg/L), NFS, ferritin (µg/L), blood count formula : leucocytes (giga/L), erythrocytes (tera/L), hemoglobin (g/L), hematocrit (%), platelets (giga/L), calciuria (mmol/L), urinary creatinin (mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ration lean mass / fat mass</measure>
    <time_frame>Month 0</time_frame>
    <description>Dual-energy X-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ration lean mass / fat mass</measure>
    <time_frame>Month 12</time_frame>
    <description>Dual-energy X-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Functional Exploration</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Functional Exploration</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thickness intima / media</measure>
    <time_frame>Month 0</time_frame>
    <description>echography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parameters of the connected watch : number of steps</measure>
    <time_frame>Month 0 and Month 6 and Month 12</time_frame>
    <description>data recovery of the connected watch</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parameters of the connected watch : distance traveled</measure>
    <time_frame>Month 0 and Month 6 and Month 12</time_frame>
    <description>data recovery of the connected watch</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parameters of the connected watch : calories consumption</measure>
    <time_frame>Month 0 and Month 6 and Month 12</time_frame>
    <description>data recovery of the connected watch</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio thickness intima / media</measure>
    <time_frame>Month 12</time_frame>
    <description>echography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>Month 0</time_frame>
    <description>Dual-energy X-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>Month 12</time_frame>
    <description>Dual-energy X-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new fractures</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new fractures</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new fractures</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new fractures</measure>
    <time_frame>Month 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new fractures</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire : PedsQL</measure>
    <time_frame>Month 0</time_frame>
    <description>Measurement Model for the Pedratric Quality of Life Inventory
The 4 Multidimensional Scales and 3 Summary Scores are
Scales Physical Functioning (8 items) Emotional Functioning (5 items) Social Functioning (5 items) School Functioning (5 items)
Summary Scores Total Scale Score (23 items) Physical Health Summary Score (8 items) Psychosocial Health Summary Score (15 items)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire : PedsQL</measure>
    <time_frame>Month 6</time_frame>
    <description>Measurement Model for the Pedratric Quality of Life Inventory
The 4 Multidimensional Scales and 3 Summary Scores are
Scales Physical Functioning (8 items) Emotional Functioning (5 items) Social Functioning (5 items) School Functioning (5 items)
Summary Scores Total Scale Score (23 items) Physical Health Summary Score (8 items) Psychosocial Health Summary Score (15 items)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire : PedsQL</measure>
    <time_frame>Month 12</time_frame>
    <description>Measurement Model for the Pedratric Quality of Life Inventory
The 4 Multidimensional Scales and 3 Summary Scores are
Scales Physical Functioning (8 items) Emotional Functioning (5 items) Social Functioning (5 items) School Functioning (5 items)
Summary Scores Total Scale Score (23 items) Physical Health Summary Score (8 items) Psychosocial Health Summary Score (15 items)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Osteogenesis Imperfecta</condition>
  <arm_group>
    <arm_group_label>Adapted sports practice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with osteogenesis imperfect will practice adapted sport twice a week during 12 months in order to improve their aerobic capacity, cardiovascular and bone benefits, and gain of quality of life.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adapted sports practices</intervention_name>
    <description>Adapted sports practices for 30 minutes twice a week</description>
    <arm_group_label>Adapted sports practice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Child with osteogenesis imperfecta

          -  Child followed in the Reference centre for constitutional bone diseases in the Hôpital
             Femme Mère Enfant

          -  Parent (s) / legal guardian who has been informed of the study and has accepted
             participation in the study by signing the consent.

          -  Patient benefiting from a social security scheme

        Exclusion Criteria:

          -  Medical and surgical contraindications to adapted physical activity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marine DESJONQUERES, MD, PhD</last_name>
    <phone>4 27 85 61 26</phone>
    <phone_ext>+33</phone_ext>
    <email>marine.fouillet-desjonqueres@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Justine Bacchetta, Pr</last_name>
    <phone>4 27 85 61 28</phone>
    <phone_ext>+33</phone_ext>
    <email>justine.bacchetta@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de Référence des Maladies Rénales Rares - Hospices Civils de Lyon - Service de Néphrologie et Rhumatologie Pédiatriques - Hôpital Femme Mère Enfant</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marine DESJONQUERES</last_name>
      <email>justine.bacchetta@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Justine BACCHETTA</last_name>
    </contact_backup>
    <investigator>
      <last_name>Marine DESJONQUERES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteogenesis imperfecta</keyword>
  <keyword>Adapted sport</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteogenesis Imperfecta</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

